Clinically Significant Ferritin Levels in C282Y/H63D Compound Heterozygotes
For C282Y/H63D compound heterozygotes, clinically significant ferritin levels are >200 µg/L in women and >300 µg/L in men, though these thresholds primarily indicate the need for further investigation rather than automatic treatment. 1, 2
Sex-Specific Thresholds
The most recent EASL 2022 guidelines establish clear diagnostic thresholds for compound heterozygotes:
- Women: Ferritin >200 µg/L combined with transferrin saturation >45%
- Men: Ferritin >300 µg/L combined with transferrin saturation >50%
These values warrant investigation for other causes of hyperferritinemia before attributing iron overload solely to the compound heterozygous genotype 2.
Critical Context: Genotype Alone Is Insufficient
The management of C282Y/H63D compound heterozygotes must be guided by phenotypic presentation and additional risk factors, not genotype alone. 1 This is fundamentally different from C282Y homozygotes, where the genetic diagnosis carries more predictive weight.
Why This Matters Clinically:
The compound heterozygous state is insufficient to cause hemochromatosis by itself 1. Research consistently demonstrates that C282Y/H63D individuals who develop significant iron overload almost always have cofactors:
- Hepatic steatosis/NAFLD
- Diabetes mellitus
- Excess alcohol consumption (>28 g/day men, >14 g/day women)
- Obesity 3, 4
In one study of 51 C282Y/H63D subjects who underwent liver biopsy, 12 of 13 with hepatic fibrosis had evidence of steatosis, excess alcohol, or diabetes 3.
Risk Stratification by Ferritin Level
Ferritin <1000 µg/L
- Low risk for cirrhosis regardless of genotype 5
- Annual monitoring with iron studies is appropriate
- Investigate and address secondary causes of elevated ferritin
Ferritin >1000 µg/L
- Requires comprehensive evaluation for other liver disease 5
- In C282Y/H63D patients, ferritin >1000 µg/L always occurred with identifiable comorbid factors in research studies 3
- Consider liver biopsy if elevated aminotransferases or other concerning features present
- 80% risk of cirrhosis in C282Y homozygotes with ferritin >1000 µg/L + elevated ALT/AST + platelets <200, but this does not apply to compound heterozygotes 5
Practical Clinical Algorithm
Step 1: Confirm elevated ferritin with repeat testing
- Women: >200 µg/L
- Men: >300 µg/L
Step 2: Measure transferrin saturation simultaneously
- Women: >45% suggests iron overload
- Men: >50% suggests iron overload
Step 3: Exclude common causes of hyperferritinemia (>90% of cases) 2:
- Chronic alcohol consumption
- Inflammation (check CRP)
- Cell necrosis (AST, ALT, CK)
- Malignancy (ESR, imaging)
- Metabolic syndrome/NAFLD (BMI, lipids, glucose, blood pressure)
Step 4: If confirmed iron overload by MRI or liver biopsy, consider phlebotomy with individualized assessment 1
Common Pitfalls to Avoid
Do not treat based on genotype alone - C282Y/H63D compound heterozygosity has low penetrance for clinically significant disease 1
Do not assume ferritin elevation equals hemochromatosis - In the general population, iron overload is NOT the most common cause of elevated ferritin 5
Do not overlook cofactors - Research shows C282Y/H63D patients with significant iron overload almost universally have additional risk factors 3, 4
Do not use the same risk stratification as C282Y homozygotes - Compound heterozygotes have significantly less biochemical and clinical expression than homozygotes 3, 4
Evidence Quality Note
The 2022 EASL guidelines 1 represent the most current expert consensus with 100% agreement on managing compound heterozygotes based on phenotype rather than genotype. The 2011 AASLD guidelines 5 provide complementary U.S.-based recommendations that align with these thresholds. Research studies 3, 4 consistently demonstrate that C282Y/H63D patients require additional insults beyond their genotype to develop clinically significant disease.